Intervention

Belimumab

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 6 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials6
Recruiting2
Common conditions6
Lead sponsors shown6
Advertisement

Clinical trials

6 shown
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyNCT07138898 · 2025-12-12
RECRUITING
Belimumab After Rituximab in Resistant Primary Juvenile SSNCT06410833 · 2024-03-09
RECRUITING
Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple SclerosisNCT04767698 · 2021-10-01
TERMINATED
Belimumab Treatment of Emphysema Patients With Anti-GRP78 AutoantibodiesNCT03244059 · 2018-08-09
COMPLETED
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's SyndromeNCT02631538 · 2016-02-17
COMPLETED
Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's SyndromeNCT01160666 · 2010-03-01
COMPLETED

Trial status mix

COMPLETED3
RECRUITING2
TERMINATED1

Phase mix

PHASE25
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.